327 related articles for article (PubMed ID: 31593975)
61. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Khan Y; Lyou Y; El-Masry M; O'Brien S
Expert Rev Hematol; 2020 Jan; 13(1):31-38. PubMed ID: 31756301
[No Abstract] [Full Text] [Related]
62. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Yeung CCS; Shadman M
Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
[TBL] [Abstract][Full Text] [Related]
63. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
64. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
Kojima K
Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
[TBL] [Abstract][Full Text] [Related]
65. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
66. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
67. [Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P; Delgado J
Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
[TBL] [Abstract][Full Text] [Related]
68. Chronic lymphocytic leukemia: a clinical review including Korean cohorts.
Jeon YW; Cho SG
Korean J Intern Med; 2016 May; 31(3):433-43. PubMed ID: 27044858
[TBL] [Abstract][Full Text] [Related]
69. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Robak P; Robak T
Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659
[TBL] [Abstract][Full Text] [Related]
70. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
71. Emerging therapies for refractory chronic lymphocytic leukemia.
Kutsch N; Hallek M; Eichhorst B
Leuk Lymphoma; 2015 Feb; 56(2):285-92. PubMed ID: 24766469
[TBL] [Abstract][Full Text] [Related]
72. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
73. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
74. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
75. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2016 Mar; 57(3):238-48. PubMed ID: 27076234
[TBL] [Abstract][Full Text] [Related]
76. Chronic Lymphocytic Leukemia: Current Concepts.
Yu EM; Kittai A; Tabbara IA
Anticancer Res; 2015 Oct; 35(10):5149-65. PubMed ID: 26408673
[TBL] [Abstract][Full Text] [Related]
77. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
78. Frontline therapies for untreated chronic lymphoid leukemia.
Liu D; Zhao J
Exp Hematol Oncol; 2019; 8():15. PubMed ID: 31428514
[TBL] [Abstract][Full Text] [Related]
79. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
80. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
